

## Transmission of Chronic Myeloid Leukemia through Peripheral-Blood Stem-Cell Transplantation

**TO THE EDITOR:** Although secondary cancer is a well-established long-term complication of hematopoietic stem-cell transplantation,<sup>1</sup> the transmission of hematologic cancers through marrow or solid-organ transplantation is exceptional.<sup>2</sup> Moreover, to our knowledge, it has not been reported after peripheral-blood stem-cell transplantation.

A nine-year-old African child received a diagnosis of sickle cell disease (hemoglobin SC) in 1991. Between 1991 and 2001, he had multiple vaso-occlusive crises, despite hydroxyurea therapy. He was referred to us at the age of 19 years for transplantation of peripheral-blood stem-cells from an HLA-identical brother who was heterozygous for sickle cell disease.<sup>3,4</sup> Before peripheral-blood stem-cell mobilization with a six-day regimen of granulocyte colony-stimulating factor at a dose of 10  $\mu$ g per kilogram of body weight, the donor's physical examination and hematologic studies were unremarkable, except for a slight inversion of the neutrophil:lymphocyte ratio, as is frequently observed in African persons (Table 1).

After conditioning with oral busulfan (16 mg per kilogram), intravenous cyclophosphamide (200 mg per kilogram), and antithymocyte globulin (90 mg per kilogram), the patient received a CD34-selected peripheral-blood stem-cell graft containing  $4 \times 10^6$  CD34+ cells per kilogram and  $0.01 \times 10^6$  CD3+ cells per kilogram. Prophylaxis against graft-versus-host disease was carried out with cyclosporine alone. The immediate post-transplantation course was complicated by cyclosporine-associated pancreatitis that resolved after the withdrawal of cyclosporine on day 21, and the patient was discharged on day 35. Neither acute nor chronic graft-versus-host disease developed.

The results of bone marrow evaluation on day 100 were normal, with more than 95 percent chimerism, but the karyotype showed a Philadelphia chromosome in 9 of 31 metaphases. Fluorescence in situ hybridization analysis confirmed the BCR-ABL rearrangement in 14 percent of marrow cells. Bone marrow evaluation in the donor showed chronic-phase chronic myeloid leukemia with the Philadelphia chromosome in 95 percent of the cells. The

recipient was treated with STI571, and a complete cytogenetic and molecular remission was achieved three and six months later, respectively. Now, more than one year after the transplantation, the patient is well, without any sign of chronic graft-versus-host disease, and is heterozygous for sickle cell disease (the status of the donor). The donor initially received interferon alfa but did not tolerate it and then received STI571; a complete cytogenetic response was achieved, but a complete molecular response has not yet occurred.

Transmission of acute myeloid leukemia as well as T-cell lymphoma through bone marrow transplantation has been reported previously.<sup>2,5</sup> However, this case shows that chronic myeloid leukemia can also be transmitted through transplantation of peripheral-blood stem cells from a donor with no sign of chronic myeloid leukemia in the peripheral blood. This raises the issue of routine bone marrow and karyotype examination in donors of peripheral-blood stem cells.<sup>4</sup> However dramatic such cases are, it would be costly and ineffective, as well

**Table 1. Hematologic Values in the Donor before and after Peripheral-Blood Stem-Cell Donation.\***

Variable	Before Donation	1 Mo after Donation	5 Mo after Donation
Hemoglobin (g/dl)	14.0	14.4	15.4
White cells ( $\times 10^9$ /liter)	7.09	5.16	16.47
Differential count (%)			
Neutrophils	34	34	37
Lymphocytes	50	47	48
Monocytes	9	10	8
Eosinophils	3	4	2
Basophils	1	1	3
Peroxidase-negative white cells	3	4	ND
Myelocytes	ND	ND	2
Platelets ( $\times 10^9$ /liter)	298	234	245
Lactate dehydrogenase $\dagger$	279	ND	492

\* ND denotes not done.

$\dagger$  The normal range is 200 to 440 U per liter.

as uncomfortable for the donor, to carry out these investigations systematically in all donors.

Frederic Baron, M.D., Ph.D.

Marie-Françoise Dresse, M.D.

Yves Beguin, M.D., Ph.D.

University of Liège  
4000 Liège, Belgium  
yves.begu@chu.ulg.ac.be

1. Curtis RE, Rowings PA, Deeg HJ, et al. Solid cancers after bone marrow transplantation. *N Engl J Med* 1997;336:897-904.

2. Niederwieser DW, Appelbaum FR, Gastl G, et al. Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia. *N Engl J Med* 1990;322:1794-6.

3. Walters MC, Patience M, Leisenring W, et al. Bone marrow transplantation for sickle cell disease. *N Engl J Med* 1996;335:369-76.

4. Vermynen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. *Bone Marrow Transplant* 1998;22:1-6.

5. Berg KD, Brinster NK, Huhn KM, et al. Transmission of a T-cell lymphoma by allogeneic bone marrow transplantation. *N Engl J Med* 2001;345:1458-63.

Correspondence Copyright © 2003 Massachusetts Medical Society.

#### INSTRUCTIONS FOR LETTERS TO THE EDITOR

Letters to the Editor are considered for publication, subject to editing and abridgment, provided they do not contain material that has been submitted or published elsewhere. Please note the following: •Letters in reference to a *Journal* article must not exceed 175 words (excluding references), must be received within three weeks after publication of the article, and must be submitted over the Internet at <https://secure.nejm.org/letters>. Letters not related to a *Journal* article must not exceed 400 words and may be submitted over the Internet or sent, typewritten and triple-spaced, by mail. •A letter can have no more than five references and one figure or table. •A letter can be signed by no more than three authors. •Financial associations or other possible conflicts of interest must be disclosed. (Such disclosures will be published with the letters. For authors of *Journal* articles who are responding to letters, this information appears in the original articles.) •Include your full mailing address, telephone number, fax number, and e-mail address with your letter.

Our address: **Letters to the Editor • New England Journal of Medicine • 10 Shattuck St. • Boston, MA 02115**

Our Web address: <https://secure.nejm.org/letters>

Our fax numbers: **617-739-9864** and **617-734-4457**

We cannot acknowledge receipt of your letter, but we will notify you when we have made a decision about publication. Letters that do not adhere to these instructions will not be considered. Rejected letters and figures will not be returned. We are unable to provide prepublication proofs. Submission of a letter constitutes permission for the Massachusetts Medical Society, its licensees, and its assignees to use it in the *Journal's* various print and electronic publications and in collections, revisions, and any other form or medium.